Introduction {#Sec1}
============

In cancer, increased promoter DNA methylation is a frequent event commonly occurring early in tumor development. Methylated DNA sequences may serve as tumor biomarkers in liquid biopsies for detecting cancer and for predicting patient prognosis \[[@CR1]\].

In 2011, we filed a patent application covering methylation of *ZNF331* (Zinc finger protein 331) as a biomarker for gastrointestinal cancers \[[@CR2]\]. *ZNF331* was shown by Yu et al. to be inactivated by promoter methylation in gastric cancer, providing the cancer cells with increased growth potential and invasiveness \[[@CR3]\]. We also found a high methylation frequency in patients with gastric cancer (80%) and to a lesser extent in patients with pancreatic cancer (40%) and cholangiocarcinomas (26%) \[[@CR4]\]. Most importantly, we reported high sensitivity (71%) and specificity (98%) for *ZNF331* methylation in colorectal cancer early 2015, strengthening the potential of *ZNF331* as a biomarker for colorectal cancer detection \[[@CR4]\]. Interestingly, these findings were recently confirmed, further supporting the biomarker potential of *ZNF331* in colorectal cancer \[[@CR5]\]. The same study also suggested aberrant promoter methylation of *ZNF331* as an independent prognostic marker for colorectal cancer, analyzing 146 samples \[[@CR5]\]. In the present study, we analyzed the effect of *ZNF331* methylation on overall survival, including altogether 423 colorectal tissue samples.

Results and discussion {#Sec2}
======================

Methylation of the *ZNF331* promoter was found in 71% (301/423) of the patients with colorectal cancer and was associated with localization in the right colon, microsatellite instability (MSI), and the *BRAF*^*V600E*^ mutation. Furthermore, *ZNF331* methylation was strongly associated with CpG island methylator phenotype (CIMP) and *MLH1* methylation (Table [1](#Tab1){ref-type="table"}). Wang et al. \[[@CR5]\] reported a similar methylation frequency of *ZNF331* in colorectal cancer (67%; 98/146). However, in contrast to our data Wang et al. did not find associations between methylated *ZNF331* and *BRAF* mutation, CIMP nor *MLH1* methylation, which may be explained by differences in sample size (Wang et al., *n* = 146; current study, *n* = 423), marker panels to define CIMP, method to identify methylation, age (median age Wang et al. 60; current study 72), and/or ethnicity (Wang et al.: Asian; current study: Caucasian).Table 1Associations between *ZNF331* methylation and clinical and molecular featuresTotalZNF331 unmethylatedZNF331 methylated*P* value*nn* (%)*n* (%)No. of patients423122 (29)301 (71)Gender0.165 Male21368 (32)145 (68) Female21054 (26)156 (74)Age0.074 \< 607026 (37)44 (63) 60--7417855 (31)123 (69) ≥ 7517541 (23)134 (77)Stage0.683 I7920 (25)59 (75) II16951 (30)118 (70) III11832 (27)86 (73) IV5619 (34)37 (66)Localization\< 0.001 Right colon16727 (16)140 (84) Left colon13047 (36)83 (64) Rectum12146 (38)75 (62)MSI status\< 0.001 MSS325111 (34)214 (66) MSI898 (9)81 (91)*BRAF*\< 0.001 *BRAF* wt356120 (34)236 (66) *BRAF* mut672 (3)65 (97)*CIMP*\< 0.001 *CIMP−*355121 (34%)234 (66) *CIMP+*650 (0)65 (100)*MLH1* methylation\< 0.001 *MLH1* unmeth360117 (32.5)243 (67.5) *MLH1* meth604 (7)56 (93)Series0.439 Oslo 35914 (24)45 (76) Oslo 2364108 (30)256 (70)*Meth* methylated, *mut* mutation, *No.* number, *unmeth* unmethylated, *wt* wild type

Wang et al. \[[@CR5]\] further reported that patients with *ZNF331* promoter methylation had a worse prognosis than patients with unmethylated promoters. Our results were in accordance with their study, although statistical significance was not reached in the multivariate Cox regression model adjusting for age and stage (HR = 1.44 (0.97--2.14), *P* = 0.069; Table [2](#Tab2){ref-type="table"}). The univariate model is presented in Fig. [1](#Fig1){ref-type="fig"} (*P* = 0.143).Table 2Multivariate Cox proportional hazard analysis with overall survival as endpointPatients, *n*Multivariate HR (95% CI)*P* valueAge \< 60701.00 (ref) 60--741761.70 (0.91--3.18)0.099 ≥ 751733.42 (1.84--6.34)\< 0.001Stage I781.00 (ref) II1681.24 (0.66--2.34)0.498 III1172.32 (1.24--4.34)0.009 IV5611.10 (5.91--20.85)\< 0.001*ZNF331* methylation *ZNF331* unmeth1211.00 (ref) *ZNF331* meth2981.44 (0.97--2.14)0.069Variables not selected by the backward likelihood method to be included in the final model: series, gender, CIMP-, MSI-, and *BRAF* mutation status*Meth* methylated, *unmeth* unmethylatedFig. 1Effect of *ZNF331* promoter methylation on overall survival modeled by the Kaplan-Meier method and compared using the log-rank test

In conclusion, in an extended series of colorectal cancer samples, we have showed the potential of promoter methylation of *ZNF331* as a biomarker for colorectal cancer detection. We have further provided data indicating a trend towards poorer prognosis for patients with *ZNF331* methylation.

Material and methods {#Sec3}
====================

Colorectal cancer tissue samples {#Sec4}
--------------------------------

This study included 423 colorectal cancer tissue samples. Fifty-nine of the samples were obtained from several different hospitals in the southeast region of Norway in the period 1987--1989 (Oslo 3 series; described in \[[@CR6]\]), and 364 of the samples were obtained from patients undergoing surgical resection at the Oslo University Hospital--Aker from 2005 to 2011 (Oslo 2 series; described in \[[@CR7], [@CR8]\]). Survival data was available for 419 patients (Oslo 3, *n* = 59; Oslo 2, *n* = 360).

Bisulfite treatment and quantitative methylation-specific PCR (qMSP) {#Sec5}
--------------------------------------------------------------------

DNA from cancer tissue samples were bisulfite treated using the EpiTect Bisulfite Kit (Qiagen), and the samples were purified using the QIAcube (Qiagen).

Quantitative methylation-specific PCR (qMSP) was used to analyze the methylation of the *ZNF331* promoter (NM_018555), with primers and probe sequences as reported earlier \[[@CR4]\]. The method was performed as previously described \[[@CR4], [@CR9]\], with the ALU-C4 element as a normalization control \[[@CR10]\]. As described in ref. \[[@CR4]\], samples with percent methylated reference (PMR) values ≥ 1 were considered methylated. Information about MSI, CIMP, *MLH1* methylation, and *BRAF* mutation status were available from previous studies \[[@CR11], [@CR12]\].

Statistical analyses {#Sec6}
--------------------

Associations between *ZNF331* methylation and clinicopathological data were analyzed by Pearson chi-square or Fisher's exact tests. For all analyses, patients were divided into three age groups (\< 60 years, 60--74 years, and ≥ 75 years). Breakpoints were chosen as previously described \[[@CR11]\]. Overall survival was used as endpoint in the survival analyses and was calculated from time of surgery until death of any cause. Cases were censored at last follow-up. The univariate effect of *ZNF331* on survival was modeled by the Kaplan-Meier method and compared using the log-rank test. A multivariate Cox's proportional hazard model was generated by a stepwise selection procedure (backward likelihood model) in order to identify a subset of relevant predictor variables from the set of available clinicopathological data (series, age, stage, gender, CIMP-, MSI-, *BRAF-*, and *ZNF331* methylation status). Hazard ratios (HRs) and 95% confidence intervals (CIs) were derived from the model, and significance of the parameters was assessed using Wald's test. To evaluate the assumption of proportionality, a chi-square test was performed. A *P* value \< 0.05 was considered statistically significant. The analyses were performed using IBM SPSS Statistics 21 and R version 3.4.1.
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